Form 4 for ICUI ICU MEDICAL INC/DE
Accepted 2024-03-11 00:00:00 ET · period of report 2024-03-07 · accession 0001669639-24-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-11 | 2024-03-07+ | ICUI | Sanzone Virginia Ruth | VP, GC | M - OptEx | $0.00 | +9,782 | 7,044 | New | $0 |
| DM | 2024-03-11 | 2024-03-07+ | ICUI | Sanzone Virginia Ruth | VP, GC | F - Tax | $105.19 | -5,362 | 5,798 | -48% | -$564.0K |
| D | 2024-03-11 | 2024-03-08 | ICUI | Sanzone Virginia Ruth | VP, GC | S - Sale+OE | $104.57 | -3,300 | 4,771 | -41% | -$345.1K |
| DM | 2024-03-11 | 2024-03-07+ | ICUI | Sanzone Virginia Ruth | VP, GC | M - OptEx | $0.00 | -9,782 | 0 | -100% | $0 |
| D | 2024-03-11 | 2024-03-08 | ICUI | Sanzone Virginia Ruth | VP, GC | A - Grant | $0.00 | +9,568 | 9,568 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-07 | M | A | 1,073 | $0.00 | 5,751 | D | — | — | (F1) These securities are Restricted Stock Units. |
| 2 | Common | Common Stock | 2024-03-07 | F | D | 587 | $105.39 | 5,164 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-07 | M | A | 6,436 | $0.00 | 11,600 | D | — | — | (F2) These Securities are Performance-based Restricted Stock Units (PRSU). |
| 4 | Common | Common Stock | 2024-03-07 | F | D | 3,529 | $105.39 | 8,071 | D | — | — | |
| 5 | Common | Common Stock | 2024-03-08 | S | D | 3,300 | $104.57 | 4,771 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.54 to $104.84, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| 6 | Common | Common Stock | 2024-03-08 | F | D | 1,246 | $104.52 | 5,798 | D | — | — | |
| 7 | Common | Common Stock | 2024-03-08 | M | A | 2,273 | $0.00 | 7,044 | D | — | — | (F2) These Securities are Performance-based Restricted Stock Units (PRSU). |
| 8 | Derivative | Common Stock | 2024-03-07 | M | D | 1,073 | $0.00 | 1,073 | D | $0.00 · 2023-03-07 to 2025-03-07 | 1,073 Common Stock | (F1) These securities are Restricted Stock Units. (F4) There is neither a purchase price nor an exercise price for the Restricted Stock Units. (F5) One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date. (F6) These are restricted stock units that fully vest 3 years from the grant date. |
| 9 | Derivative | Performance Shares | 2024-03-08 | M | D | 2,273 | $0.00 | 0 | D | $0.00 · 2023-03-08 to 2024-03-08 | 2,273 Common Stock | (F2) These Securities are Performance-based Restricted Stock Units (PRSU). (F7) There is neither a purchase price nor an exercise price for the PRSUs. (F9) These PRSUs were granted on March 8, 2021. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs vest on March 8 of the first, second, and third year following the year of grant. |
| 10 | Derivative | Performance Shares | 2024-03-07 | M | D | 6,436 | $0.00 | 0 | D | $0.00 · — to 2024-03-07 | 6,436 Common Stock | (F2) These Securities are Performance-based Restricted Stock Units (PRSU). (F7) There is neither a purchase price nor an exercise price for the PRSUs. (F8) These PRSUs were granted on March 7, 2022 and had a 2-year cliff-vest performance period subject to the satisfaction of performance-based metrics and continuous services through the vest date. The PRSUs were approved for vesting in February 2024 by the Compensation Committee at 200% of the original grant. |
| 11 | Derivative | Common Stock | 2024-03-08 | A | A | 9,568 | $0.00 | 9,568 | D | — · — to — | 9,568 Common Stock | (F1) These securities are Restricted Stock Units. (F4) There is neither a purchase price nor an exercise price for the Restricted Stock Units. (F5) One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date. (F6) These are restricted stock units that fully vest 3 years from the grant date. |